US FDA update on Novo Nordisk's Victoza delayed again
This article was originally published in Scrip
Executive Summary
Novo Nordisk says it will provide a formal update of the US FDA's feedback on its GLP-1 analogue Victoza (liraglutide) by February 2nd, when it announces its 2009 financial results, after having been unable to meet its previous predicted timelines.